Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameMedtide
Stock Code03880
Company Full NameMedtide Inc.
Industry醫療保健
Principal Activities公司主要提供(i)CRO服務,即多肽NCE發現合成;及(ii)CDMO服務,即多肽CMC開發以及商業化生產。
Listing Date2025-06-30
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市錢塘區12號大街69號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.medtideinc.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 30.60 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 3,060
Par ValueTo be extracted
Offer Period2025-06-20 to 2025-06-25
Global Offering Shares16,800,000 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share15.3%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 514,080,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 3,060
2 lots 200 HK$ 6,120
3 lots 300 HK$ 9,180
4 lots 400 HK$ 12,240
5 lots 500 HK$ 15,300
6 lots 600 HK$ 18,360
7 lots 700 HK$ 21,420
8 lots 800 HK$ 24,480
9 lots 900 HK$ 27,540
10 lots 1,000 HK$ 30,600
15 lots 1,500 HK$ 45,900
20 lots 2,000 HK$ 61,200
25 lots 2,500 HK$ 76,500
30 lots 3,000 HK$ 91,800
35 lots 3,500 HK$ 107,100
40 lots 4,000 HK$ 122,400
45 lots 4,500 HK$ 137,700
50 lots 5,000 HK$ 153,000
60 lots 6,000 HK$ 183,600
70 lots 7,000 HK$ 214,200
80 lots 8,000 HK$ 244,800
90 lots 9,000 HK$ 275,400
100 lots 10,000 HK$ 306,000
200 lots 20,000 HK$ 612,000
300 lots 30,000 HK$ 918,000
400 lots 40,000 HK$ 1,224,000
500 lots 50,000 HK$ 1,530,000
600 lots 60,000 HK$ 1,836,000
700 lots 70,000 HK$ 2,142,000
800 lots 80,000 HK$ 2,448,000
900 lots 90,000 HK$ 2,754,000
1,000 lots 100,000 HK$ 3,060,000
1,500 lots 150,000 HK$ 4,590,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 200,000 HK$ 6,120,000
2,500 lots 250,000 HK$ 7,650,000
3,000 lots 300,000 HK$ 9,180,000
3,500 lots 350,000 HK$ 10,710,000
4,000 lots 400,000 HK$ 12,240,000
4,500 lots 450,000 HK$ 13,770,000
5,000 lots 500,000 HK$ 15,300,000
6,000 lots 600,000 HK$ 18,360,000
7,000 lots 700,000 HK$ 21,420,000
8,400 lots 840,000 HK$ 25,704,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 3.12B
Est. Threshold HK$ 9.73B
Analysis Result HK market cap below threshold, need +211%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 387.18 million
Listing Expenses~HK$ 84,381,000
Listing Expenses / Funds Raised~17.0%
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 30.8
First Day OpenHK$ 30.3
First Day Change0.65%
First Day Volume8593800.0
First Day Turnover272301000.0
Use of Proceeds
1、約76.4%(或314.0百萬港元)將用于在美國及中國建設設施以進一步擴大公司服務能力及產能; 2、約4.1%(或16.9百萬港元)將用于擴張中國的產能; 3、約9.5%(或39.2百萬港元)將用于在更多地區建立銷售及售后服務網點,以豐富公司全球業務及擴大公司客戶群; 4、約10.0%(或41.1百萬港元)將用于公司營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 CLSA LIMITED CE AAB893
Joint Bookrunners (5)
Morgan Stanley Asia Limited CE AAD291 CLSA LIMITED CE AAB893 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 PRIME SECURITIES LIMITED (HK) CE ACX574 东吴证券国际经纪有限公司 CE AYA587
Joint Lead Managers (6)
Morgan Stanley Asia Limited CE AAD291 CLSA LIMITED CE AAB893 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 PRIME SECURITIES LIMITED (HK) CE ACX574 东吴证券国际经纪有限公司 CE AYA587 ARISTO SECURITIES LIMITED CE BDH167

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Welight Capital L.P. 39,244,500 HKD — 7.63% — 6 months 2025-12-30
2 佳曦控股有限公司 39,244,500 HKD — 7.63% — 6 months 2025-12-30

Directors & Management

PositionChinese nameEnglish Name
Chairman徐琪—
Company Secretary李玲梅,吳東澄—
No director data available.

Major Shareholders

Major Shareholders & Holdings琪康國際有限公司(42.01%),杭州海鼎科技有限公司(10.87%),李湘莉(7.24%),衢州海邦肽達創業投資合伙企業(有限合伙)及杭州海邦博源創業投資合伙企業(有限合伙)(6.69%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO of Tede Medicine (03880) attracted substantial retail interest, with an oversubscription ratio of 301.15 times across 70,338 valid applications, indicating vigorous demand. However, the reported hit rate of 0.0% appears anomalous given the high oversubscription and likely stems from incomplete source data. The reallocation trigger and clawback to Tier C further confirm strong retail enthusiasm. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Tier distribution details are unavailable in the provided data, making precise anomaly analysis impossible. With mechanism Type A (old) and Clawback Tier C triggered, it is common for the boundary between 甲尾 and 乙头 to be narrow, but no specific lot sizes or winner ratios are available to confirm inefficiencies or compare broker fee efficiency across tiers. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic data is entirely missing, with total holders, mainland participation, and Hong Kong percentages all recorded as zero. In similarly oversubscribed IPOs, mainland Chinese investors often dominate, but here no conclusions can be drawn about age, gender, or regional concentration like Guangdong. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Medtide (03880) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect